JG
MRTX

Jefferies Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Jefferies Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2.56M Sell
36,600
-8,000
-18% -$592K 0.02% 524
2022
Q2 		$2.99M Sell
44,600
-94,200
-68% -$5.99M 0.02% 494
2022
Q1 		$11.4M Buy
138,800
+108,200
+354% +$11.1M 0.07% 211
2021
Q4 		$4.49M Hold
30,600
– – 0.03% 492
2021
Q3 		$5.41M Sell
30,600
-4,500
-13% -$724K 0.04% 412
2021
Q2 		$5.67M Sell
35,100
-3,200
-8% -$514K 0.04% 427
2021
Q1 		$6.56M Sell
38,300
-152,500
-80% -$30.2M 0.06% 294
2020
Q4 		$41.9M Buy
190,800
+13,300
+7% +$2.88M 0.33% 39
2020
Q3 		$29.5M Buy
177,500
+36,200
+26% +$4.95M 0.33% 35
2020
Q2 		$16.1K Hold
141,300
– – 0.19% 73
2020
Q1 		$10.9M Sell
141,300
-5,000
-3% -$448K 0.12% 139
2019
Q4 		$18.9M Buy
146,300
+21,800
+18% +$2.1M 0.15% 121
2019
Q3 		$9.7M Buy
124,500
+94,500
+315% +$8.87M 0.08% 229
2019
Q2 		$3.09M Buy
30,000
+27,800
+1,264% +$2.16M 0.02% 707
2019
Q1 		$161K Buy
+2,200
New +$150K ﹤0.01% 2008
2018
Q4 		– Sell
-29,400
Closed -$1.39M – 2686
2018
Q3 		$1.39M Buy
+29,400
New +$1.64M 0.01% 1160

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group's MRTX Position: Q3 2022 in Review

Jefferies Group increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 114% in Q3 2022, buying an estimated $831K and bringing the position to 21,049 shares worth $1.47M. The position accounts for 0.01% of the portfolio, ranked #698.

Jefferies Group first reported a position in MRTX in Q3 2018 and has held it in 14 quarters since. The position peaked at $21.4M in Q4 2020. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

  • Jefferies Group held 21,049 shares of Mirati Therapeutics, Inc. Common Stock worth $1.47M as of Q3 2022.
  • Jefferies Group bought 11,233 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $831K.
  • Mirati Therapeutics, Inc. Common Stock made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #698 holding.
  • Jefferies Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and has held it in 14 quarters since.
  • Jefferies Group's Mirati Therapeutics, Inc. Common Stock position peaked at $21.4M in Q4 2020.
  • 243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.